Quantification of surrogate monoclonal antibodies in mouse serum using LC–MS/MS

Surrogate monoclonal antibodies (mAbs) used in preclinical studies can be challenging to quantify due to lack of suitable immunoaffinity reagents or unavailability of the mAb protein sequence. Generic immunoaffinity reagents were evaluated to develop sensitive LC–MS/MS assays. Peptides of unknown se...

Full description

Saved in:
Bibliographic Details
Published in:Bioanalysis 2021-02, Vol.13 (3), p.147-164
Main Authors: Mehl, John T, Landry, France, Discenza, Lorell, Sleczka, Bogdan, Zhao, Qihong, Shuster, David J, Madia, Priyanka, DasGupta, Ruchira, Rajendran, Surendran, Sun, Huadong, Ciccimaro, Eugene, Olah, Timothy V
Format: Article
Language:English
Subjects:
affinity capture
hybrid LC–MS
ignotum peptide
LC–MS
monoclonal antibodies
quantification
quantitation
surrogate mAbs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Surrogate monoclonal antibodies (mAbs) used in preclinical studies can be challenging to quantify due to lack of suitable immunoaffinity reagents or unavailability of the mAb protein sequence. Generic immunoaffinity reagents were evaluated to develop sensitive LC–MS/MS assays. Peptides of unknown sequence can be used for selective LC–MS quantification. anti-mouse IgG1 was found to be an effective immunoaffinity reagent, enabling quantification of mouse IgG1 mAbs in mouse serum. Selective peptides of unknown sequence were applied for multiplex LC–MS quantification of two rat mAbs co-dosed in mouse. Generic anti-mouse IgG subtype-specific antibodies can be used to improve assay sensitivity and peptides of unknown sequence can be used to quantify surrogate mAbs when the mAb protein sequence in unavailable.
ISSN:1757-6180
1757-6199
DOI:10.4155/bio-2020-0297